ArticlebioRxiv : the preprint server for biology2021
Negligible impact of SARS-CoV-2 variants on CD4
Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 156 citations in OpenAlex.
- Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.PLoS biology · 2022Article
- Article
- Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications.Current microbiology · 2021Review
- Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus.PLoS biology · 2021Article
- Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination.Nature reviews. Immunology · 2021Review
- Seeing SARS-CoV-2 variants through the eyes of T cells.Nature reviews. Immunology · 2021Article
- Why are some coronavirus variants more infectious?Journal of biosciences · 2021Review
- Novel Highly Divergent SARS-CoV-2 Lineage With the Spike Substitutions L249S and E484K.Frontiers in medicine · 2021Article
- Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity.Frontiers in microbiology · 2021Article
Corrections and comments
- Updated by
Authors and funding
18 authors at 3 institutions in 2 countries.
Funding
Abstract
The emergence of SARS-CoV-2 variants highlighted the need to better understand adaptive immune responses to this virus. It is important to address whether also CD4+ and CD8+ T cell responses are affected, because of the role they play in disease resolution and modulation of COVID-19 disease severity. Here we performed a comprehensive analysis of SARS-CoV-2-specific CD4+ and CD8+ T cell responses from COVID-19 convalescent subjects recognizing the ancestral strain, compared to variant lineages B.1.1.7, B.1.351, P.1, and CAL.20C as well as recipients of the Moderna (mRNA-1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines. Similarly, we demonstrate that the sequences of the vast majority of SARS-CoV-2 T cell epitopes are not affected by the mutations found in the variants analyzed. Overall, the results demonstrate that CD4+ and CD8+ T cell responses in convalescent COVID-19 subjects or COVID-19 mRNA vaccinees are not substantially affected by mutations found in the SARS-CoV-2 variants.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.